December 5, 2024
Theratechnologies to license Ionis’ RNA-targeted therapies in Canada
Theratechnologies has entered into a licensing agreement with Ionis Pharmaceuticals to acquire exclusive Canadian rights for two investigational RNA-targeted medicines, olezarsen and donidalorsen.